ArticleCurrent topics in microbiology and immunology2013
Antimicrobial efflux pumps and Mycobacterium tuberculosis drug tolerance: evolutionary considerations.
Article in Current topics in microbiology and immunology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 80 citations in OpenAlex.
- Key Proteins and Enzymatic Mechanisms Underlying Drug Resistance in Mycobacterium tuberculosis.Advances in experimental medicine and biology · 2026Review
- Beyond antibiotic resistance: The whiB7 transcription factor coordinates an adaptive response to alanine starvation in mycobacteria.Cell chemical biology · 2024Article
- Revolutionizing control strategies against Mycobacterium tuberculosis infection through selected targeting of lipid metabolism.Cellular and molecular life sciences : CMLS · 2023Review
- Beyond antibiotic resistance: thebioRxiv : the preprint server for biology · 2023Article
- Vanoxerine kills mycobacteria through membrane depolarization and efflux inhibition.Frontiers in microbiology · 2023Article
- Tuberculosis challenges: Resistance, co-infection, diagnosis, and treatment.European journal of microbiology & immunology · 2022Review
- Variants associated with Bedaquiline (BDQ) resistance identified in Rv0678 and efflux pump genes in Mycobacterium tuberculosis isolates from BDQ naïve TB patients in Pakistan.BMC microbiology · 2022Article
- The evolving biology ofFrontiers in cellular and infection microbiology · 2022Review
- Unraveling the mechanisms of intrinsic drug resistance inFrontiers in cellular and infection microbiology · 2022Review
- Advances in adjunct therapy against tuberculosis: Deciphering the emerging role of phytochemicals.MedComm · 2021Review
- Investigating GhanaianAntibiotics (Basel, Switzerland) · 2021Article
- Transporters Involved in the Biogenesis and Functionalization of the Mycobacterial Cell Envelope.Chemical reviews · 2021Review
- Targeting theFrontiers in microbiology · 2021Review
- Mesenchymal Stem Cells and Tuberculosis: Clinical Challenges and Opportunities.Frontiers in immunology · 2021Review
- Mechanisms of Drug-Induced Tolerance in Mycobacterium tuberculosis.Clinical microbiology reviews · 2020Review
- Physicochemical properties andRSC medicinal chemistry · 2020Review
- Mannose receptor targeted bioadhesive chitosan nanoparticles of clofazimine for effective therapy of tuberculosis.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2020Article
- Human mesenchymal stem cell based intracellular dormancy model of Mycobacterium tuberculosis.Microbes and infection · 2020Article
- The effect of anti-tuberculosis drugs therapy on mRNA efflux pump gene expression ofNew microbes and new infections · 2019Article
- Repositioning rifamycins for Mycobacterium abscessus lung disease.Expert opinion on drug discovery · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
The need for lengthy treatment to cure tuberculosis stems from phenotypic drug resistance, also known as drug tolerance, which has been previously attributed to slowed bacterial growth in vivo. We discuss recent findings that challenge this model and instead implicate macrophage-induced mycobacterial efflux pumps in antimicrobial tolerance. Although mycobacterial efflux pumps may have originally served to protect against environmental toxins, in the pathogenic mycobacteria, they appear to have been repurposed for intracellular growth. In this light, we discuss the potential of efflux pump inhibitors such as verapamil to shorten tuberculosis treatment by their dual inhibition of tolerance and growth.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.